Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2012

01-06-2012 | Perspectives

The Genetic Information Nondiscrimination Act (GINA): Public Policy and Medical Practice in the Age of Personalized Medicine

Author: Eric A. Feldman, JD, PhD

Published in: Journal of General Internal Medicine | Issue 6/2012

Login to get access

Abstract

Survey data suggest that many people fear genetic discrimination by health insurers or employers. In fact, such discrimination has not yet been a significant problem. This article examines the fear and reality of genetic discrimination in the United States, describes how Congress sought to prohibit such discrimination by passing the Genetic Information Nondiscrimination Act of 2008 (GINA), and explores the implications of GINA for general internists and their institutions. It concludes that medical providers and health care institutions must be familiar with the general intent and specific terms of GINA, and should continue to collect genetic information that can contribute to the high quality provision of medical treatment. Not doing so violates their medical mission and diminishes the quality of care patients deserve.
Literature
1.
go back to reference Regulations Under the Genetic Information Nondiscrimination Act of 2008, 75 Fed. Reg. 68912 (2010). Regulations Under the Genetic Information Nondiscrimination Act of 2008, 75 Fed. Reg. 68912 (2010).
2.
go back to reference Haga SB, Carrig MM, O'Daniel JM, et al. Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling. J Gen Intern Med. 2011;26:834–40.PubMedCrossRef Haga SB, Carrig MM, O'Daniel JM, et al. Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling. J Gen Intern Med. 2011;26:834–40.PubMedCrossRef
3.
go back to reference Hudson KL, Holohan MK, Collins FS. Keeping pace with the times — The Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661–63.PubMedCrossRef Hudson KL, Holohan MK, Collins FS. Keeping pace with the times — The Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661–63.PubMedCrossRef
4.
go back to reference Protecting Workers from Genetic Discrimination: Hearing Before the Subcommittee on Health, Employment, Labor, and Pensions, Committee on Education and Labor, U.S. House of Representatives, 110th Cong., 1st Sess. 33–35 (2007) (prepared statement of Dean Karen Rothenberg). Protecting Workers from Genetic Discrimination: Hearing Before the Subcommittee on Health, Employment, Labor, and Pensions, Committee on Education and Labor, U.S. House of Representatives, 110th Cong., 1st Sess. 33–35 (2007) (prepared statement of Dean Karen Rothenberg).
5.
go back to reference S.Rep.No.110-48, 110th Cong., 1st Sess. 6 (2007). S.Rep.No.110-48, 110th Cong., 1st Sess. 6 (2007).
6.
go back to reference They appear to have had significant public support. “Besides the more than 200 health advocacy and business organizations that support this bill, recent surveys show 93 percent of Americans believe that employers and insurers should not be able to use genetic information to discriminate.” 153 Cong. Rec. 10310, 10323 (permanent ed. Apr. 25 2007) (statement of Rep. Biggert). They appear to have had significant public support. “Besides the more than 200 health advocacy and business organizations that support this bill, recent surveys show 93 percent of Americans believe that employers and insurers should not be able to use genetic information to discriminate.” 153 Cong. Rec. 10310, 10323 (permanent ed. Apr. 25 2007) (statement of Rep. Biggert).
7.
go back to reference Genetic Information Nondiscrimination Act of 2008 , Pub.L. 110–233, 122 Stat. 881 (2008). Genetic Information Nondiscrimination Act of 2008 , Pub.L. 110–233, 122 Stat. 881 (2008).
8.
go back to reference Korobkin R, Rajkumar R. The Genetic Information Nondiscrimination Act — A half-step toward risk sharing. N Engl J Med. 2008;359:335–37.PubMedCrossRef Korobkin R, Rajkumar R. The Genetic Information Nondiscrimination Act — A half-step toward risk sharing. N Engl J Med. 2008;359:335–37.PubMedCrossRef
9.
go back to reference For a European example, see Hoyweghen IV, Horstman K. European practices of genetic information and insurance: Lessons for the Genetic Information Nondiscrimination Act. JAMA. 2008; 300:326–27. For a European example, see Hoyweghen IV, Horstman K. European practices of genetic information and insurance: Lessons for the Genetic Information Nondiscrimination Act. JAMA. 2008; 300:326–27.
10.
go back to reference Patient Protection and Affordable Care Act, Pub.L. 111–148, 124 Stat. 119 (2010). Patient Protection and Affordable Care Act, Pub.L. 111–148, 124 Stat. 119 (2010).
11.
go back to reference 42 U.S.C.A. §300gg-3(b)(1)(B) (2010) (“Genetic information shall not be treated as a condition described in subsection (a)(1) of this section in the absence of a diagnosis of the condition related to such information”). Like many parts of PPACA, the preexisting condition exclusion is undergoing legal review. 42 U.S.C.A. §300gg-3(b)(1)(B) (2010) (“Genetic information shall not be treated as a condition described in subsection (a)(1) of this section in the absence of a diagnosis of the condition related to such information”). Like many parts of PPACA, the preexisting condition exclusion is undergoing legal review.
12.
go back to reference Roberts JL. Preempting discrimination: lessons from the Genetic Information Nondiscrimination Act. Vanderbilt Law Rev. 2010;63:439–90. Roberts JL. Preempting discrimination: lessons from the Genetic Information Nondiscrimination Act. Vanderbilt Law Rev. 2010;63:439–90.
13.
go back to reference This view is strongly stated by Senator Kennedy in S.Rep.No.110-48, 110th Cong., 1st Sess. 7 (2007): “Although surveys and polls demonstrate a fairly widespread fear of discrimination, there is little evidence or documentation of actual discrimination in health insurance.” This view is strongly stated by Senator Kennedy in S.Rep.No.110-48, 110th Cong., 1st Sess. 7 (2007): “Although surveys and polls demonstrate a fairly widespread fear of discrimination, there is little evidence or documentation of actual discrimination in health insurance.”
14.
go back to reference Kaufmann MB. Genetic discrimination in the workplace: an overview of existing protections. Loyola Univ Chicago Law J. 1999;30(393–438):402–03. Kaufmann MB. Genetic discrimination in the workplace: an overview of existing protections. Loyola Univ Chicago Law J. 1999;30(393–438):402–03.
16.
go back to reference The Genetic Information Nondiscriminiation Act: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce, U.S. House of Representatives, 110th Cong., 1st Sess. 33 (2007) (prepared statement of Sharon Terry, Chair, Coalition for Genetic Fairness, and President, Chief Executive Officer, Genetic Alliance, Washington, DC). Id. at 4095. The Genetic Information Nondiscriminiation Act: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce, U.S. House of Representatives, 110th Cong., 1st Sess. 33 (2007) (prepared statement of Sharon Terry, Chair, Coalition for Genetic Fairness, and President, Chief Executive Officer, Genetic Alliance, Washington, DC). Id. at 4095.
17.
go back to reference S.Rep.No.110-48, 110th Cong., 1st Sess. 6 (2007). S.Rep.No.110-48, 110th Cong., 1st Sess. 6 (2007).
18.
go back to reference S.Rep.No.110-48, 110th Cong., 1st Sess. 7 (2007). S.Rep.No.110-48, 110th Cong., 1st Sess. 7 (2007).
19.
go back to reference S.Rep.No.110-48, 110th Cong., 1st Sess. 6–8 (2007). According to the report, 63% of respondents to a national telephone survey indicated that they would refuse genetic tests if health insurers or employers could gain access to the results, and 68% of patients answering a questionnaire said that fear of discrimination would keep them from billing their health insurance companies for genetic tests. For similar reasons, the AMA welcomed the passage of GINA, stating that “This new law will allow patients to take advantage of scientific advances in genetics, such as screenings and therapies, without worrying that their personal health information could be used against them by insurers or employers” (statement by Edward Langston, AMA Board Chair: AMA applauds passage of new law to protect patients from genetic discrimination [Internet]. Sussex: UK: Medical News Today; c2011 [posted 2008 May 23; cited 2011 Sep 16]. Available from: 2008 http://www.medicalnewstoday.com/releases/108633.php). It also appears that many people are unaware of the existence of genetic testing (Baer HJ, Brawarsky P, Murray MF, Haas JS. Familial risk of cancer and knowledge and use of genetic testing. J Gen Intern Med. 2010; 25:717–24). S.Rep.No.110-48, 110th Cong., 1st Sess. 6–8 (2007). According to the report, 63% of respondents to a national telephone survey indicated that they would refuse genetic tests if health insurers or employers could gain access to the results, and 68% of patients answering a questionnaire said that fear of discrimination would keep them from billing their health insurance companies for genetic tests. For similar reasons, the AMA welcomed the passage of GINA, stating that “This new law will allow patients to take advantage of scientific advances in genetics, such as screenings and therapies, without worrying that their personal health information could be used against them by insurers or employers” (statement by Edward Langston, AMA Board Chair: AMA applauds passage of new law to protect patients from genetic discrimination [Internet]. Sussex: UK: Medical News Today; c2011 [posted 2008 May 23; cited 2011 Sep 16]. Available from: 2008 http://​www.​medicalnewstoday​.​com/​releases/​108633.​php). It also appears that many people are unaware of the existence of genetic testing (Baer HJ, Brawarsky P, Murray MF, Haas JS. Familial risk of cancer and knowledge and use of genetic testing. J Gen Intern Med. 2010; 25:717–24).
21.
go back to reference See Bullock v. Spherion, No. 3:10-cv-465, 2011 WL 1869933 (W.D.N.C. May 16, 2011); Robinson v. Starplex/CMS Event Security, No. CV-10-723-HU, 2011 WL 1541290 (D. Or. Mar. 15, 2011); Citron v. Niche Media/Ocean Drive Magazine, No. 10-24014-CIV, 2011 WL 381939 (S.D. Fla. Feb. 2, 2011); Benoit v. Pennsylvania Board of Probation and Parole-West Division, No. 094047, 2010 WL 481021 (E.D. Pa. Feb. 9, 2010); Capulong v. Dep’t of Education of Guam, No. 10–00005, 2011 WL 1134986 (D. Guam Mar. 24, 2011); Armes v. CSX Transportation, Inc., No. CCB-11-112, 2011 WL 2471476 (D. Md. June 20, 2011). See Bullock v. Spherion, No. 3:10-cv-465, 2011 WL 1869933 (W.D.N.C. May 16, 2011); Robinson v. Starplex/CMS Event Security, No. CV-10-723-HU, 2011 WL 1541290 (D. Or. Mar. 15, 2011); Citron v. Niche Media/Ocean Drive Magazine, No. 10-24014-CIV, 2011 WL 381939 (S.D. Fla. Feb. 2, 2011); Benoit v. Pennsylvania Board of Probation and Parole-West Division, No. 094047, 2010 WL 481021 (E.D. Pa. Feb. 9, 2010); Capulong v. Dep’t of Education of Guam, No. 10–00005, 2011 WL 1134986 (D. Guam Mar. 24, 2011); Armes v. CSX Transportation, Inc., No. CCB-11-112, 2011 WL 2471476 (D. Md. June 20, 2011).
22.
25.
go back to reference See, for example: Regulations Under the Genetic Information Nondiscrimination Act of 2008, 75 Fed. Reg. 68912 (2010). See, for example: Regulations Under the Genetic Information Nondiscrimination Act of 2008, 75 Fed. Reg. 68912 (2010).
Metadata
Title
The Genetic Information Nondiscrimination Act (GINA): Public Policy and Medical Practice in the Age of Personalized Medicine
Author
Eric A. Feldman, JD, PhD
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2012
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-012-1988-6

Other articles of this Issue 6/2012

Journal of General Internal Medicine 6/2012 Go to the issue

Healing Arts: Materia Medica

Access to Care: Too Much or Not Enough?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.